The world’s first vaccine against the deadly respiratory syncytial virus could be ready in a matter of months, scientists have said.
However, GlaxoSmithKline (GSK) is now just months away from publishing results which it expects will show that its latest RSV jab is safe and effective.
Data is due in early 2022, and the vaccine is expected to be approved and in use by next winter.
Dr Jamila Louahed, the vice-president of vaccine research and development at GSK, told The Telegraph that the pharmaceutical company has been working towards this moment for decades, and is now on the verge of a breakthrough.
“We have to wait for the data to be certain, but I am quite comfortable saying there is a high probability that the vaccine will work,” she said.